Managing Director of Longitude Capital
Josh Richardson, MD, is a Managing Director with Longitude Capital. Dr. Richardson currently serves on the boards of Neurana Pharmaceuticals and Sublimity Therapeutics and has been involved with a number of Longitude investments, including Aimmune Therapeutics (AIMT), Collegium Pharmaceuticals (COLL), Cadence Pharmaceuticals (CADX, acquired by Mallinckrodt), InfaCare Pharmaceutical (acquired by Mallinckrodt) and Precision Dermatology (acquired by Valeant Pharmaceuticals).
Dr. Richardson was previously a consultant with McKinsey & Company and a Public Equities Analyst at HealthCor Management where he managed small and mid-cap biotechnology investments.
Dr. Richardson holds an MD from the University of Virginia and a B.S. in biomedical science from the University of South Florida.